NCT06911866 - A Phase Ib Study of RC1416 Injection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

October 26, 2025

Study Completion Date

January 2, 2026

Conditions

Moderate to Severe Asthma

Interventions

DRUG

RC1416

there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

DRUG

RC1416 Placebo

Each subjects will receive the placebo once by subcutaneous injection.

Trial Locations (18)

100029

RECRUITING

China-Japan Friendship Hospital, Beijing

RECRUITING

China-japan Friendship Hospital, Beijing

Unknown

RECRUITING

Peking University Shougang Hospital, Beijing

RECRUITING

Shenzhen People's Hospital, Shenzhen

RECRUITING

The First Affiliated Hospital of Guilin Medical University, Guilin

RECRUITING

Hebei Petro China Centre Hospital, Langfang

RECRUITING

Hebei Province Hospital of Chinese Medicine, Shijiazhuang

RECRUITING

Nanyang Central Hospital, Nanyang

RECRUITING

Xinxiang First People's Hospital, Xinxiang

RECRUITING

The First Affiliated Hospital of Baotou Medical College, Baotou

RECRUITING

Nanjing First Hospital, Nanjing

RECRUITING

Jining NO.1 people's hospital, Jining

RECRUITING

Liaocheng People's Hospital, Liaocheng

RECRUITING

Zibo Municipal Hospital, Zibo

RECRUITING

Shanxi Bethune Hospital, Taiyuan

RECRUITING

Hangzhou First People's Hospital, Hangzhou

RECRUITING

Hangzhou First People's Hospital, Hangzhou

RECRUITING

The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

Nanjing RegeneCore Biotech Co., Ltd.

INDUSTRY